Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Neovascularisation Migrates to Fellow Eye at Same Rate Regardless of Treatment Choice: Presented at ARVO By Cameron E. Johnston FORT LAUDERDALE, Fla -- April 29, 2008 -- A well-documented risk with choroidal neovascularisation (CNV) resulting from age-related macular degeneration (AMD) is that in time, the CNV will spread to the fellow eye, eventually leaving the patient with impaired vision in both eyes. A major question for physicians and patients has been how -- or whether -- the spread of the CNV to the fellow eye can be prevented or slowed. Investigators now report that there is no difference in the time to progression from unilateral to bilateral disease among patients who are treated with verteporfin photodynamic therapy (PDT) or the more expensive vascular endothelial growth factor (VEGF) inhibitors, bevacizumab and ranibizumab. The researchers presented these results in a poster presentation here on April 27 at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2008). According to Irene Barbazetto, MD, Fellow, Department of Ophthalmology, Columbia University, New York, New York, 5% to 8% of patients with choroidal neovascularisation secondary to age-related macular degeneration will develop CNV in the fellow eye within a year of diagnosis. By the second year, 15% will have CNV in both eyes, and by the end of 5 years, 45% will have CNV in both eyes. Dr. Barbazettos and colleagues conducted a review of the charts from 219 patients who were treated with intravitreal ranibizumab or bevacizumab, and 120 patients who received PDT and were used as the control group. There were no differences in baseline patient characteristics or lesion characteristics in the 2 groups. Results of the analysis showed that after 1 year, the risk of developing CNV in the fellow eye was 0.06 for patients receiving anti-VEGF therapy and 0.05 for patients treated with PDT. Over a 2-year period, Kaplan-Meier analysis indicated the probability of the disease spreading to the fellow eye to be 0.22 among patients receiving a VEGF inhibitor and 0.19 among patients treated with PDT. "This means the anti-VEGF therapies may not reduce the risk of developing CNV in the fellow eye any more than the PDT does," Dr. Barbazetto said. It was interesting to note that the rate at which the disease spread to the fellow eye was lower than has been seen in historical controls, including data from the Age-Related Eye Disease Study. [Presentation title: Risk for Choroidal Neovascularization in the Fellow Eye of Patients on Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration. Poster A565] E-mail this page to a friend or colleague! To print, use this version